Search icon

RALPHVR INC.

Company claim

Is this your business?

Get access!

Company Details

Name: RALPHVR INC.
Legal type: Foreign Corporation
Status: Active
Standing: Good
Profit or Non-Profit: Profit
File Date: 16 Feb 2016 (9 years ago)
Authority Date: 16 Feb 2016 (9 years ago)
Last Annual Report: 14 Apr 2025 (2 months ago)
Organization Number: 0944430
Industry: Engineering, Accounting, Research, Management & Related Services
Number of Employees: Small (0-19)
ZIP code: 40507
City: Lexington
Primary County: Fayette County
Principal Office: 348 EAST MAIN STREET, LEXINGTON, KY 40507
Place of Formation: DELAWARE

President

Name Role
Richard E Hoagland President

Registered Agent

Name Role
RICHARD HOAGLAND Registered Agent

Secretary

Name Role
Richard E Hoagland Secretary

Treasurer

Name Role
Richard E Hoagland Treasurer

Vice President

Name Role
Richard E Hoagland Vice President

Assumed Names

Name Status Expiration Date
VRTogether Active 2027-09-17

Filings

Name File Date
Registered Agent name/address change 2025-04-14
Annual Report 2025-04-14
Annual Report 2024-03-27
Annual Report 2023-03-27
Certificate of Assumed Name 2022-09-17

USAspending Awards / Financial Assistance

Date:
2024-09-17
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
VIRTUAL PARTNER (PROVIDE, ACTIVATE, RESTORE, TRACK, INSPIRE, EDUCATE, REHABILITATE): MULTI-COMPONENT VIRTUAL REALITY APPLICATION TO TARGET A REDUCTION IN DELIRIUM IN THE INTENSIVE CARE UNIT. - PROJECT SUMMARY DELIRIUM COMMONLY PLAGUES PATIENTS IN THE HOSPITAL. PATIENTS IN THE INTENSIVE CARE UNIT (ICU) HAVE THE HIGHEST RISKS FOR DELIRIUM, ESTIMATED TO BE BETWEEN 70% TO 80%. THE EFFECTS OF DELIRIUM ARE PROFOUND, WITH HIGHER 12- MONTH MORTALITY RATES FOLLOWING DISCHARGE, SIGNIFICANT INCREASES IN ICU LENGTH OF STAY, DURATION OF MECHANICAL VENTILATION, RISK OF LONG-TERM COGNITIVE IMPAIRMENTS, AND REDUCED QUALITY OF LIFE AFTER DISCHARGE. DELIRIUM ALSO LEADS TO CHALLENGES FOR ICU STAFF INCLUDING AGITATION AND COMBATIVE BEHAVIOR. THERE ARE SEVERE FINANCIAL COSTS FROM DELIRIUM AS WELL, WITH HIGHER HEALTHCARE COSTS PER PATIENT AND AN ADDITIONAL BURDEN ON THE AMERICAN HEALTHCARE SYSTEM OF UP TO $152 BILLION EACH YEAR. THESE STATISTICS ILLUSTRATE THAT AN INNOVATIVE AND EFFECTIVE INTERVENTION STRATEGY TO PREVENT DELIRIUM IN THE ICU IS HIGHLY SIGNIFICANT AND IMMEDIATELY CLINICALLY IMPACTFUL. NON-PHARMACOLOGICAL MULTICOMPONENT INTERVENTIONS (WHICH MAY INCLUDE PATIENT MOBILIZATION, COGNITIVE STIMULATION, SLEEP OPTIMIZATION, AND MORE) HAVE BEEN SHOWN TO REDUCE THE ODDS OF INCIDENT DELIRIUM IN HOSPITALIZED NON-CRITICALLY ILL PATIENTS BY APPROXIMATELY HALF. HOWEVER, SUCH MULTICOMPONENT INTERVENTIONS PLACE AN ADDITIONAL BURDEN ON THE ALREADY CONSTRAINED RESOURCES OF NURSING STAFF. TECHNOLOGY-BASED INTERVENTIONS MAY BE EFFECTIVE INTERVENTION DELIVERY MECHANISMS, BUT THESE TECHNOLOGY INTERVENTIONS MUST BE MULTICOMPONENT AND NOT OVERBURDEN STAFF. CRUCIALLY, AN INTERVENTION MUST BE MULTICOMPONENT, CAN BE TAILORED TO SPECIFIC PATIENT CHARACTERISTICS, TARGETS THE PHYSICAL, COGNITIVE, EMOTIONAL, AND SOCIAL NEEDS OF THE PATIENT, AND DOES NOT OVERBURDEN NURSING STAFF. RALPHVR IS APPLYING TO THIS PHASE I SBIR TO ACHIEVE THREE SPECIFIC AIMS. AIM 1: EMPLOY FOCUS GROUPS COMPRISED OF STAFF INVOLVED IN THE TREATMENT OF DELIRIUM IN THE ICU (N=12) AND FORMER ICU PATIENTS (N=12) FOR EXPERT, STAKEHOLDER, AND PATIENT FEEDBACK AND INSIGHT TO INFORM DEVELOPMENT. AIM 2: DEVELOP A FRAMEWORK FOR THREE INNOVATIONS AND DEVELOP THREE MIND BODY INTERVENTION (MBI) COMPONENTS, THEN COMBINE THESE SOFTWARE SYSTEMS INTO A SINGLE VR APPLICATION (THE VIRTUAL PARTNER PROTOTYPE). AIM 3: RUN A FEASIBILITY STUDY TARGETING PATIENTS IN THE ICU (N=22). THREE LONG-TERM OBJECTIVES MUST BE MET TO BRING VIRTUAL PARTNER TO MARKET: 1) DETERMINE THE SAFETY AND FEASIBILITY OF VIRTUAL PARTNER TO BE DELIVERED TO PATIENTS IN THE ICU, 2) DETERMINE VIRTUAL PARTNERS’S EFFICACY TO PROMOTE TARGET OUTCOMES THROUGH SUCCESSFUL DELIVERY OF MBIS, AND 3) DETERMINE THE EFFICACY OF VIRTUAL PARTNER AS AN INTERVENTION TO REDUCE THE OCCURRENCE OF, AND TREAT, DELIRIUM. SUCCESSFULLY COMPLETING THE LONG-TERM GOALS AND AIMS WILL RESULT IN A CLINICALLY VALIDATED INTERVENTION TO TREAT DELIRIUM IN THE ICU. THE PROPOSAL ADDRESSES A GAP IN CURRENT CLINICAL PRACTICE AND RESPONDS TO THE NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH) PROGRAM PRIORITY AREA OF HEALTH PROMOTION, DISEASE PREVENTION, HEALTH RESTORATION, AND RESILIENCE. THE PROPOSED VR PLATFORM FOR PATIENTS IN THE ICU DIRECTLY ADDRESSES MULTIPLE NCCIH RESEARCH PRIORITY AREAS, MOST NOTABLY DEVELOPMENT AND TESTING OF INNOVATIVE TECHNOLOGIES FOR MULTISENSORY DELIVERY OF AN MBI.
Obligated Amount:
254892.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-09-19
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
VRSINGTOGETHER: DIGITAL THERAPEUTIC VIRTUAL REALITY TOOL TO MITIGATE THE EFFECTS OF ALZHEIMER'S DISEASE (AD) AND ALZHEIMER'S-DISEASE-RELATED DEMENTIAS (ADRD) - PROJECT SUMMARY ONE IN THREE SENIORS DIE WITH ALZHEIMER’S DISEASE (AD) OR ALZHEIMER’S DISEASE RELATED DEMENTIAS (ADRD). MORE THAN SIX MILLION AMERICANS ARE LIVING WITH AD AND BY 2050 THIS NUMBER IS PROJECTED TO RISE TO NEARLY 13 MILLION. THE ECONOMIC COSTS OF AD ARE SIGNIFICANT, WITH 355 BILLION IN NATIONAL COSTS FOR CARING FOR PEOPLE WITH AD AND ADRD. DISCONCERTINGLY, THERE IS ALSO AN ESTIMATED 256 BILLION IN CARE PROVIDED BY FAMILY MEMBERS AND OTHER UNPAID CAREGIVERS. THESE STATISTICS ILLUSTRATE THE NECESSITY FOR SCALABLE STRATEGIES AND INTERVENTIONS TO DELAY THE ONSET OF AND HALT THE PROGRESSION OF, AD AND ADRD. INDEED, A 2020 REPORT BY THE LANCET INDICATED THAT 40% OF DEMENTIA CASES COULD BE PREVENTED BY MODIFYING LIFESTYLE FACTORS; WITH A RECOMMENDATION FOR INDIVIDUALS TO MAINTAIN COGNITIVE, PHYSICAL, AND SOCIAL ACTIVITY THROUGH MIDLIFE AND BEYOND. CRUCIALLY, INTERVENTIONS SHOULD BE INITIATED AS EARLY IN THE DISEASE PROCESS AS POSSIBLE—IN THOSE WITH NORMAL COGNITION OR ONLY MILD COGNITIVE IMPAIRMENT (MCI)—AS THE EFFECTS OF LIFESTYLE FACTORS ON DEMENTIA ONSET ARE CUMULATIVE. IN FACT, THE MCI DESIGNATION ITSELF WAS DEVELOPED TO SIGNAL THAT A PATIENT IS AT HIGHER RISK FOR AD/ADRD, PROMPTING ENHANCED CARE. IMPORTANTLY, EXISTING SOLUTIONS LEVERAGING TECHNOLOGY LACK THE ABILITY TO COMBINE PHYSICAL, COGNITIVE, AND SOCIAL MODALITIES TOGETHER DUE TO THE INABILITY TO FOSTER MEANINGFUL SOCIAL CONNECTION AND CO-PRESENCE. IN-PERSON PROGRAMS CAN FOSTER MEANINGFUL SOCIAL CONNECTIONS AND CO-PRESENCE. UNFORTUNATELY, THESE SOLUTIONS ARE ONLY ACCESSIBLE TO THOSE WITH THE TIME, MONEY, AND GEOGRAPHY TO HAVE ACCESS, AND FURTHERMORE, THESE SOLUTIONS CANNOT SCALE EFFECTIVELY. TO ADDRESS THE SIGNIFICANT UNMET NEED FOR A MULTI-MODAL INTERVENTION TO DELAY THE ONSET OF AND HALT THE PROGRESSION OF AD AND ADRD, RALPHVR IS DEVELOPING VRSINGTOGETHER, A SCALABLE DIGITAL THERAPEUTIC THAT FOSTERS SOCIAL ENGAGEMENT, MENTAL ACTIVITY, AND PHYSICAL ACTIVITY WITH MUSIC, SINGING, AND LIGHT PHYSICAL ACTIVITY THROUGH RHYTHMIC ELEMENTS IN A COLLABORATIVE AND SHARED VIRTUAL SPACE. VRSINGTOGETHER IS A NETWORKED (MULTI-USER) VR APPLICATION TO BE OFFERED ON LOW-COST COMMERCIALLY AVAILABLE VR HEADSETS. RALPHVR IS APPLYING FOR THIS NIA PHASE I SBIR TO ACHIEVE THREE SPECIFIC AIMS. AIM 1: EMPLOY A FOCUS GROUP OF EXPERTS TO GENERATE CRITICAL INSIGHTS FOR RALPHVR TO DEVELOP A DESIGN DOCUMENT. AIM 2: DEVELOP THE VRSINGTOGETHER PROTOTYPE. AIM 3: INVESTIGATE THE FEASIBILITY AND USABILITY OF VRSINGTOGETHER IN PATIENTS WITH AGE-RELATED MCI (=65 YEARS OF AGE) AND THE INDIVIDUALS WHO CARE FOR THEM (=18 YEARS OF AGE). THREE LONG-TERM OBJECTIVES MUST BE MET TO BRING VRTOGETHER TO MARKET: 1) DETERMINE THE FEASIBILITY OF VRSINGTOGETHER TO MITIGATE THE EFFECTS OF AD AND ADRD, 2) DETERMINE VRSINGTOGETHER’S EFFICACY TO PROMOTE LIGHT PHYSICAL, COGNITIVE, AND SOCIAL ACTIVITY, AND 3) DETERMINE THE EFFICACY OF VRSINGTOGETHER AS AN INTERVENTION TO SLOW OR HALT THE ONSET OF AD AND ADRD. SUCCESSFULLY COMPLETING THE LONG-TERM GOALS AND AIMS WILL RESULT IN A CLINICALLY VALIDATED SCALABLE AND LOW-COST INTERVENTION TO MITIGATE THE EFFECTS OF AD AND ADRD.
Obligated Amount:
452016.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-08-09
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: DIGITAL THERAPEUTIC VIRTUAL REALITY TOOL TO ADDRESS SOCIAL ISOLATION AND IMPROVE GERIATRIC CARE (COVID-19)
Obligated Amount:
272082.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-04-30
Awarding Agency Name:
Small Business Administration
Transaction Description:
ECONOMIC INJURY DISASTER GRANT
Obligated Amount:
1000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks

Serial Number:
87164719
Mark:
DAYDREAM BLUE
Status:
Abandoned because the applicant failed to respond or filed a late response to an Office action. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2016-09-08
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
DAYDREAM BLUE

Goods And Services

For:
Computer software in the field of playing video games; Virtual reality game software; Virtual reality software in the field of entertainment; Virtual reality software for playing computer games; Downloadable video game programs
First Use:
2015-09-24
International Classes:
009 - Primary Class
Class Status:
ACTIVE
Serial Number:
98754878
Mark:
VRTOGETHER
Status:
NON-FINAL ACTION - MAILED
Mark Type:
TRADEMARK
Application Filing Date:
2024-09-17
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
VRTOGETHER

Goods And Services

For:
Downloadable augmented reality software for multiple users to interact; Computer software platforms, recorded, for development and/or operation of extended reality, including mixed reality, virtual reality, and augmented reality; Downloadable computer software platforms for development and/or operat...
First Use:
2021-08-07
International Classes:
009 - Primary Class
Class Status:
Active

Reviews Leave a review

This company hasn't received any reviews.

Financial Incentive

Program Program Status Average Hourly Wage Project Cost Incentive Amount Initial Jobs New Jobs Date of Action Approval Type
SBIR/STTR Inactive - $99,819 $99,819 - - 2024-01-01 Final
Angel Investment Tax Credit Inactive - $0 $5,000 - - 2023-03-30 Final
SBIR/STTR Inactive - $80,000 $80,000 - - 2022-01-01 Final

Sources: Kentucky Secretary of State